Indivina (Medroxyprogesterone Acetate, Estradiol Valerate)

Medroxyprogesterone acetate binds to progesterone receptors, delivering progestogenic activity, while estradiol valerate is converted to estradiol, activating estrogen receptors. Together they restore hormonal balance, alleviating menopausal symptoms and preventing excessive endometrial growth.

The specific dose and regimen of Indivina are determined by the prescribing clinician based on individual patient factors, therapeutic goals, and local prescribing guidelines. Patients should follow the prescriber’s instructions exactly.

Indivina is intended for post‑menopausal hormone replacement and is not recommended for use during pregnancy or lactation. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Indivina combines a progestogen (medroxyprogesterone acetate) with an estrogen (estradiol valerate) in a single oral formulation, offering both symptom relief and endometrial protection. Compared with estrogen‑only products, it reduces the risk of endometrial hyperplasia, while its oral route may be preferred over transdermal or injectable alternatives for some patients.

Indivina tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight to maintain potency throughout the shelf life.

Indivina is taken orally, usually once daily, with or without food, as directed by the prescriber. Patients should swallow the tablet whole with water and avoid crushing or chewing unless specifically instructed.

Serious risks include venous thromboembolism, stroke, and liver dysfunction. Patients with a history of clotting disorders, cardiovascular disease, or liver disease should be closely monitored, and any signs of serious adverse events should prompt immediate medical evaluation.

Indivina is contraindicated in women with known or suspected hormone‑dependent cancers (e.g., breast or uterine cancer), active thromboembolic disease, severe liver impairment, or unexplained vaginal bleeding. It should also be avoided in pregnant or breastfeeding women.